Molecular changes in malignant tissue can lead to an increase in the expression levels of
various proteins or receptors that can be used to target the disease. In oncology, diagnostic …

This review outlines the accomplishments and potential developments of targeted alpha (α)
particle therapy (TAT). It discusses the therapeutic advantages of the short and highly …

Abstract Background Beta-emitting Lu-177-labeled prostate-specific membrane antigen
(PSMA) radioligand therapy (RLT) is a new option for metastatic castration-resistant prostate …

Molecular alterations in malignant disease result in the expression or upregulations of
various targets that can be used for imaging and treatment with radiopharmaceuticals. This …

Rationale: Despite the success of several standards of care treatment options in metastatic
castration-resistant prostate cancer (mCRPC), a significant number of patients attain …

Metastatic prostate carcinoma overexpresses prostate-specific membrane antigen (PSMA),
making this antigen a suitable target for radioligand therapy of the disease. Here we report …

Simple Summary Monoclonal antibodies (mAbs) have the ability to specifically target tumor-
cell antigens. This unique property has led to their use in the delivery of radioisotopes to …

Prostate-specific membrane antigen (PSMA)-targeted PET imaging for prostate cancer with
68 Ga-labeled compounds has rapidly become adopted as part of routine clinical care in …

Treatment of advanced metastatic castration-resistant prostate cancer after failure of
approved therapy options remains challenging. Prostate-specific membrane antigen (PSMA) …

Purpose: Prostate-specific membrane antigen (PSMA) is an attractive target for radionuclide
therapy of metastatic castration-resistant prostate cancer (mCRPC). PSMA-targeted alpha …